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Background
Heart failure (HF) management guided by CardioMEMS™ pulmonary artery
pressure (PAP) monitoring reduces PAP and HF hospitalizations. The objective of
this project was to characterize the relationship between medication adjustments,
PAP change, and outcomes for all patients at an advanced HF center.
Methods
We retrospectively analyzed medication changes and hospitalizations for 32
consecutive patients implanted with the CardioMEMS™ sensor at a single HF
center and related these outcomes to PAP data from the Merlin.net (Abbott)
database. Absolute change in PAP from baseline was estimated using area under
the curve normalized to days monitored.
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Results
Patients had an average change in mean PAP of -3.9±1.3 mmHg at 6 months and
-5.7±2.1 mmHg at 12 months. Compared to the pre-implant time period, hospital
days for HF-related hospitalizations decreased by 6.9 (95% CI = 3.3-10.5) days
per patient at 6 months (p<0.001) and 7.9 (95% CI = 4.3-11.5) days per patient at
12 months (p<0.001). Over 12 months, patients with baseline PAP 25-35mmHg
and >35mmHg experienced a drop in PAP while their number of medication
adjustments decreased, and patients with baseline PAP <25mmHg experienced a
rise in PAP and an increase in medication adjustments.
Conclusion
PAP-guided HF management involved time-varying intensity of medication
changes, which correlated with sustained reductions in hospital stay.
Keywords: heart failure, hemodynamics, pulmonary artery, CardioMEMS,
outcomes

Introduction
Despite advances in pharmacologic and device therapies, heart failure (HF)
remains a progressive syndrome associated with high rates of hospitalization and
mortality, poor quality of life, and staggering health care costs.1 An important
hemodynamic feature of HF is elevation of the left ventricular end-diastolic
pressure that can lead to secondary elevation of pulmonary artery pressure.2
Regardless of the left ventricular ejection fraction, pressure elevation is closely
associated with symptom burden, hospitalizations, and mortality.3-5 Strategies to
manage HF guided by non-invasive surrogates of hemodynamics have been
unsuccessful.6, 7, 8
In the CHAMPION (CardioMEMS™ Heart Sensor Allows Monitoring of Pressure to
Improve Outcomes in NYHA Class III Heart Failure Patients) trial, HF management
guided by ambulatory pulmonary artery pressure (PAP) monitoring using a
wireless implantable sensor (CardioMEMS™ Heart Failure System, Abbott)
decreased HF-related hospitalizations six months after implant, compared to
control patients receiving standard care.9 Following commercial approval of the
sensor, real world studies showed that CardioMEMS™ implantation is associated
with meaningful reductions in PAP and, separately, HF hospitalizations.10, 11
Although ambulatory hemodynamic monitoring has shown promise, the optimal
use and implementation in routine clinical practice remains to be defined.
Significant uncertainty remains over patient selection, the frequency and intensity
of medication adjustment required to affect PAP, the relationship at a patient level
between PAP change and clinical outcomes, and the magnitude and durability of
clinical benefit. These uncertainties have lead to calls for comprehensive, real
world studies to fully assess the impact of this device.12
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In the present study, we report our experience with the CardioMEMS™ system at
a non-transplant advanced HF program operating within a large health care
system. We examine changes in PAP for up to 12 months following
CardioMEMS™ implant and relate longitudinal PAP changes to baseline
hemodynamics, medication adjustment, and clinical outcomes.

Methods
Patients and data source
Patients selected for implant with the CardioMEMS™ sensor met the following
criteria: New York Heart Association (NYHA) class III chronic heart failure; at least
one HF-related hospitalization in the year prior to implant; life expectancy >1 year;
GFR >25 ml/min/1.73 m2 ; responsive to diuretics; expected to be adherent to daily
pressure monitoring and staff instructions; and could be reliably contacted by
telephone. According to institutional practice, patients were eligible only after
management by the institution’s board-certified HF cardiologists to achieve
maximally tolerated medical and device therapy per professional guidelines. The
CardioMEMS™ Heart Failure System (Abbott, Sylmar, California) was then
implanted by one of two HF specialists and managed by the same HF team,
comprised of 2 HF physicians and 2 clinic nurses, according to institution-specific
general management guidelines. The study was approved by the Providence
Health & Services Oregon institutional review board, with waiver of informed
consent.
Between January 2015 and December 2016, 32 patients received a
CardoMEMS™ sensor at our facility. We performed chart reviews of these
consecutive patients to collect demographic and baseline hemodynamic data, as
well as hospitalization history one year prior to the implant and medication
adjustments post implant. The study cutoff date for retrospective chart review was
2/20/2017. A request to retrieve the PA pressure data for these patients from the
Abbott Merlin.net database was submitted. A copy of the PA pressure data was
harvested in May 2017 when the request was approved; thus the pressure dataset
includes an additional 2-3 months of data beyond the hospitalizations and
medication adjustments dataset. Pressure data contains the date and time of each
pressure reading transmission, along with derived pressure measures (mean,
systolic, and diastolic PAP). No patients were lost to follow-up.
Pressure management
Following sensor implant, an initial mean PAP goal of <25 mmHg was targeted.
Patients’ pressures were then monitored every 2 to 3 days on Merlin.net by a
registered nurse. In general, adjustments in medications were made with approval
from a supervising HF cardiologist based on a center-specific treatment protocol
(Appendix), in conjunction with lab testing, patient symptoms, and clinical
judgment. Adjustments in medication were communicated to patients by phone or
in person, if during a clinic visit.
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Statistical Analysis
The effectiveness of the pressure monitoring in managing the PAP was assessed
using the area under the curve (AUC) methodology described by Heywood et al.10
The pressure data from the first week after implant was used as the baseline. A
time series of PAP was generated for each patient, with linear interpolation
between data points. The AUC was computed for the area between the PAP
timeline and baseline PAP for each patient, starting either from the time of implant
to the desired time point or within the time interval of a selected time window (e.g.
3-6 months). Because AUC is a measure of cumulative change (mmHg-day) and
is time-interval duration dependent, we further calculated the pressure change
from baseline for each patient by dividing AUC by the number of days in the time
interval (normalized change in PAP, mmHg). For subgroup analyses, patients
were categorized by baseline mean PAP (<25 mmHg, 25-35 mmHg, and >35
mmHg), gender, or left ventricle ejection fraction (LVEF) status, defined as HF with
preserved ejection fraction (HFpEF) = EF ≥40% and HF with reduced ejection
fraction (HFrEF) = EF <40%. Both AUC and change in PAP were reported as
mean ± SE.
The clinical outcomes of all-cause and HF-related hospitalizations (planned and
unplanned) were compared pre- and post-implant. For a selected time window
(e.g., 6-12 months), only patients with post-implant follow-up time long enough for
this window were included in the pre- vs. post-implant comparison. The average
number of days for all-cause and HF-related hospitalizations within a certain time
window pre- and post-implant was compared using paired t-tests. Rates of
hospitalization within 12 months pre- and post-implant were compared using the
Anderson-Gill regression modeling for recurrent events, taking into account withinsubject correlations with robust variance estimate.13 One patient who died at 2.4
months after the implant was excluded in the hospitalization rate analysis; LVAD
patients were included in the analysis. Subgroup analyses for hospitalization rate
were performed for patients grouped by baseline PAP, gender, LVEF status, and
age <75 years old. Due to the small sample sizes in the subgroups, the time
window for subgroup analyses was limited to 6 months.
Total medication adjustments within drug classes during the study period were
reported; types of adjustments involving loop diuretics were further characterized.
To explore the relationship between medication adjustments and PAP changes
over time, the average change in PAP for each of the three baseline mean PAP
groups in the time windows of 0-3, 3-6, 6-9, and 9-12 months post implant, were
calculated and graphed as a function of time. The average number of medication
adjustments for each baseline PAP group in the corresponding time interval was
calculated and the PAP markers were sized relative to this number. Medication
adjustments over time and change in PAP over time was also graphed for
individual patients, grouped by baseline PAP. In these graphs, closed markers
indicate that the patient had an HF-related hospitalization in the time window and
open markers indicate an absence of HF-related hospitalization. To avoid bias in
these calculation due to incomplete follow-up data, only patients with long enough
follow-up time for both medication adjustments and pressure data to cover the
selected time window were included in that time window. The R statistical program
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(www.r-project.org, R Foundation for Statistical Computing, Vienna, Austria) was
used for all analyses. Figures were created in Adobe Illustrator CC 2014.

Results
Patient population
From January 2015 through December 2016, 32 patients were implanted with
CardioMEMS™ at our center (Table 1). The average age was 66 years old, 50%
were female, and the majority of patients (62.5%) had HFrEF. The majority of
patients had comorbidities and laboratory data that indicated mild to moderate
renal insufficiency. Patients in our clinic were actively managed for HF prior to
CardioMEMS implant, as indicated by the high number of HFrEF patients
prescribed evidence-based therapies at baseline.
Table 1: Patient demographics
Variable
# of patients implanted
Age, years, mean ± SD, median (range)
Gender, female, n (%)

Values
32
66.6 ± 10.2, 66 (40-88)
16 (50%)

Race, white, n (%)

30 (93.8%)

BMI, kg/m2, mean ± SD

33.8 ± 9.5

Preserved EF, n (%)

13 (40.6%)

Comorbidities, n (%)
Coronary artery disease

18 (56.3%)

ICD or pacemaker

16 (50%)

Diabetes mellitus

17 (53.1%)

Lung disease

21 (65.6%)

Laboratory data, mean ± SD
Sodium

137.9 ± 3.2

BUN

36.9 ± 22.0

Creatinine

1.47 ± 0.47

Baseline hemodynamics, mean ± SD
Right atrial pressure, mmHg

12.6 ± 7.1

Cardiac index, L/min/m2

2.63 ± 0.81

Cardiac output, L/min

5.54 ± 2.10
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Baseline PAP, n (%)
< 25 mmHg

6 (18.8%)

25 – 35 mmHg

13 (40.6%)

≥ 35 mmHg

13 (40.6%)

Medications, for HFrEF patients*, n (%)
Beta blocker

10 (91%)

ACEI or ARB or ARNI

10 (91%)

Spironolactone

6 (55%)

Implant approach, n (%)
Femoral vein

13 (40.6)

Internal jugular vein

19 (59.4)

Follow-up time, months, median (range)

12.6 (2.3-25.0)

* Excluding 8 patients with stage 4-5 chronic kidney disease (n=5) and VAD
patients (n=3)
ACEI = angiotensin-converting enzyme inhibitor, ARB = angiotensin receptor blockers,
ARNI = angiotensin receptor-neprilysin inhibitor, BMI = body mass index, BUN = blood
urea nitrogen, EF = ejection fraction, HFrEF = heart failure reduced ejection fraction, ICD =
implantable cardioverter defibrillator, PAP = pulmonary artery pressure, SD = standard
deviation

Eighty-one percent of patients had baseline PAP above normal (>25 mmHg) and
41% had baseline PAP >35 mmHg. The majority of patients (60%) were implanted
via the internal jugular vein. The median follow-up time was 12.6 months. Three
patients treated with durable left ventricular assist devices (LVAD) at least 12
months prior to sensor implant were included; exclusion of these patients did not
impact the major results from any analyses, thus these patients were included to
increase sample size. There were no procedure-related, device-related, or systemrelated complications.
One patient deteriorated and underwent LVAD implantation two months after
sensor implant. One patient died two and a half months after implant from
combined septic/cardiogenic shock. An additional five deaths occurred after one
year post-implant, with causes of death including renal failure, progressive heart
failure, out-of-hospital cardiac arrest, bowel perforation, and cause unknown.
Pulmonary artery pressure changes
Cumulative changes in PAP over time were measured using the area under the
curve (AUC) method previously described (Supplemental Figure 1).10 We further
calculated normalized AUC, which represents the absolute change in mean PAP

The VAD Journal: https://doi.org/10.13023/vad.2019.01

Page 6 of 15

The VAD Journal: The journal of mechanical assisted circulation and heart failure

from baseline, which can easily be compared across different time-interval lengths.
For the overall population, average change in PAP was -3.9 ± 1.3 mmHg at 6
months and -5.7 ± 2.1 mmHg at 12 months (Figure 1A). Patients with the highest
baseline PAP (>35 mmHg) had the greatest drop in pressure at 12 months (-10.4 ±
3.5 mmHg, compared to baseline), while patients with the lowest baseline PAP
(<25 mmHg) had a slight increase in pressure at 12 months (2.0 ± 3.0 mmHg,
compared to baseline; Figure 1B).

Figure 1: Changes in pulmonary artery pressures over time. Absolute pressure
change over time, reported as mean PAP AUC normalized by days monitored per
patient, averaged for the overall population (A) and for each baseline pressure group
(B). For both graphs, solid line indicates average pressure and shaded area indicates
95% confidence intervals. Data tables report mean ± SE (number of patients). AUC =
area under the curve, PAP = pulmonary artery pressure.
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Sustained PAP reductions over time were observed in both male and female
patients and in patients with reduced and preserved EF (Supplemental Figure 2).
There was no difference in baseline PAP between HFrEF and HFpEF patients
(HFpEF mean ± SD = 32.5 ± 13.7, HFrEF mean ± SD = 35.2 ± 9.0, p=0.56).
Hospitalizations
Cumulative incidence of HF-related hospitalization pre- and post-implant is
presented in Figure 2. For the overall patient population, sensor implant was
associated with a 72% reduction in the risk of HF-related hospitalizations at 12
months (hazard ratio (HR) [95% confidence interval] = 0.28 [0.14-0.55]; p=0.002).
The reduction in HF-related hospitalization at 6 months post-implant, compared to
the pre-implant time period, was significant when patients were stratified by
baseline PAP, gender, EF status, and age.
Figure 2 – Reduction in
cumulative HF-related
hospitalizations. (A) Sustained
decrease in cumulative HF-related
hospitalizations up to 12 months
post-implant for all patients (n=17).
(B) 6-month hazard ratios for postvs pre-implant HF-related
hospitalizations by subgroup
(n=25). CI = confidence interval, EF =
ejection fraction, HF = heart failure, HR
= hazard ratio, PAP = pulmonary artery
pressure.
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Figure 3 shows the pre- and post-implant timeline of hospitalizations, grouped into
3-month intervals. The average number of hospital days for all-cause and HFrelated hospitalizations increased during the pre-implant time period, peaking in
the 3 months prior to implantation. Following sensor implantation, there was an
immediate decrease in the number of hospital days for all-cause and HF-related
hospitalizations, which was sustained over one year. Compared to the pre-implant
time period, hospital days for all-cause hospitalizations decreased by 7.4 days per
patient (95% CI = 2.3-12.6; p=0.007) and hospital days for HF-related
hospitalizations decreased by 6.9 days per patient (95% CI = 3.3-10.5; p<0.001) at
6 months post-implant (Table 2). At 12 months post-implant, hospital days for allcause hospitalizations decreased by 7.2 days per patient (95% CI = 2.2-12.2;
p=0.008) and hospital days for HF-related hospitalizations decreased by 7.9 days
per patient (95% CI = 4.3-11.5; p<0.001), compared to the pre-implant time period
(Table 2).

Figure 3: Significant decrease in hospital days post-implant. Time line of the
average number of hospital days for all-cause (A) and HF-related (B)
hospitalizations pre- (red) and post-implant (blue).
Adherence and medication adjustments
Over the study period, patients transmitted data 9,959 times over 12,370 patientdays, for an average of one transmission every 1.24 days. Time between
transmissions was 0.96 days in the first 30 days post-implant, 1.12 days in 6
months post-implant, and 1.15 days in one year post-implant. Median utilization,
defined as the percentage of weeks with at least one transmission,9 was 100%
(IQR = 96.1-100%) at 6 months follow up and 97.7% (IQR = 94.6-100%) at one
year follow up.
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Table 2: Hospital days for all-cause and HF-related hospitalizations, pre- and
post-implant
All-cause hospitalizations
Pre/post
implant time
frame

Days per
patient,
post-implant

Reduction
(95% CI)

p-value

Total days,
pre-implant

Total days,
post-implant

Days per
patient,
pre-implant

6 months
(n=25)

270

84

10.8

3.4

7.4
(2.3-12.6)

0.007

12 months
(n=17)

211

89

12.4

5.2

7.2
(2.2-12.2)

0.008

Reduction
(95% CI)

p-value

HF-related hospitalizations
Pre/post
implant time
frame

Total days,
pre-implant

Total days,
post-implant

Days per
patient,
pre-implant

Days per
patient,
post-implant

6 months
(n=25)

222

49

8.9

2.0

6.9
(3.3-10.5)

<0.001

12 months
(n=17)

189

55

11.1

3.2

7.9
(4.3-11.5)

<0.001

CI = confidence interval
There were 282 medication adjustments over the study period, with an average of
1.5 patient-months between adjustments. The average number of medication
adjustments per patient per month was 0.82 ± 0.65 for the overall patient
population and less than one for each of the baseline PAP subgroups. The
majority of medication adjustments were in loop diuretics (53.9%, 152
adjustments) and other diuretics (16.3%, 46 adjustments) (Supplemental Figure 3).
For loop diuretics, 48.3% (75 adjustments) were increases in dose and 30.3% (46
adjustments) were decreases.
Relationship between pressure changes, medication adjustments, and
hospitalizations
We stratified patients according to baseline PAP (<25 mm Hg, 25-35 mm Hg, and
>35 mm Hg) and analyzed the relationship between pressure changes over time
and medication adjustments (Figure 4). Patients with low baseline PAP (<25
mmHg) had an average of 1.8 and 2.0 medication adjustments for the first 0-3 and
3-6 months post-implant, respectively, which rose to 5.0 medication adjustments at
9-12 months post-implant. This group experienced an average increase in PAP of
4.8 mmHg at 9-12 months post-implant. Conversely, patients with the highest
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pressures at baseline (>35 mmHg) had an average of 3.5 medication adjustments
at 0-3 months, but only required 1.3 medication adjustments at 9-12 months.
These patients experienced an average drop in PAP of 5.1 mmHg in the first 0-3
months and 11.5 mmHg at months 9-12. Patients with intermediate baseline PAP
(25-35 mmHg) started out with the greatest average number of medications
adjustments (4.3) in the first 0-3 months but required the smallest average number
of adjustments (1.1) at 9-12 months. These patients experienced an average drop
in PAP of 6.4 mmHg at 9-12 months post-implant.

Figure 4 – Average pressure change and medication adjustments over time
for each baseline pressure group. The average number of medication
adjustments for each pressure group at each time point is included within the
marker, and the marker size is scaled accordingly. AUC = area under the curve,
PAP = pulmonary artery pressure.
Supplemental Figure 4 provides patient-level data on medication adjustments,
pressure changes, and HF-related hospitalizations for patients grouped by
baseline pressure. Patients with >35 mmHg baseline PAP experienced more HFrelated hospitalizations at multiple time points post-implant. Conversely, patients
with baseline normal PAP experienced an increase in PAP yet did not require
hospitalization. Notably, several patients in all three pressure groups experienced
no change in PAP over time, despite increased medication adjustments.

Discussion
In this cohort of consecutive patients implanted with a CardioMEMSTM sensor at a
single advanced HF center, we found that device implant was associated with
The VAD Journal: https://doi.org/10.13023/vad.2019.01

Page 11 of 15

The VAD Journal: The journal of mechanical assisted circulation and heart failure

significant overall reductions in PA pressure. Although variability was observed in
individual pressure changes, patients with abnormal baseline PAP (>25mmHg)
experienced reductions in PAP while the number of medication adjustments
decreased over time, whereas patients with normal baseline PAP experienced a
rise in PAP and required more medication adjustments over time. Consistent with
randomized and observational studies, we found a substantial reduction in
cumulative HF-related hospitalizations at 6 and 12 months post-implant compared
to the pre-implant period. Adding to these previous studies, we report a reduction
of 7.2 days per patient for all-cause and 7.9 days per patient for HF
hospitalizations at 12 months after implant.
In this cohort, the majority of all-cause hospitalizations in the pre-implant time
frame were HF-related, which is reflected in the reduction in the number and days
of all-cause hospitalizations post-implant. The decrease in HF-related
hospitalizations did not result in an increase in non-HF-related hospitalizations.
The reduction in all-cause hospitalization is in agreement with previous analyses.11
Of considerable interest, number of hospital days for all-cause and HF-related
hospitalization was dramatically reduced after sensor implant. There are several
potential explanations for these findings. First, patients readmitted with HF were
likely to be hospitalized in an earlier stage of decompensation given longitudinal
knowledge of PA pressure. Secondly, CardioMEMS patients can have their sensor
interrogated during hospitalization at the discretion of the managing physician. It is
therefore possible that knowledge of changes in PAP during hospitalization
impacted the decision of when to discharge. Finally, ambulatory hemodynamic
management of HF can improve common co-morbidities in HF patients.14 Non-HF
admissions for common comorbidities could conceivably be shorter as a result of
improvement in HF and ability to interrogate PA pressure.
This is the first study to report patient-level interactions between hemodynamics,
medication adjustments, and clinical outcomes. Although the absolute reductions
in PA pressure observed in the studied population are numerically modest, the
association with substantial clinical benefit (e.g. fewer hospitalizations) is
consistent with an analysis by Zile et al which showed that even a 5 mmHg
reduction in PA diastolic pressure is associated with a 30% mortality reduction.15
Costanzo et al reported that patients with higher baseline PA diastolic pressures
had more medication adjustments than those with lower baseline pressures.16 In
contrast, our patients in the highest baseline pressure stratum had fewer
medication adjustments over time, particularly at 6-12 months post-implant as
pressures plateaued. Conversely, in the small cohort of patients with normal
baseline pressures, more medication changes were required over time. These
findings likely reflect the approach at our center to attempt aggressive lowering of
PAP in the first few months after implant.
We found that despite multiple medication adjustments, some patients in each
pressure stratum had no change in PAP, and for those in the highest pressure
stratum, inability to reduce pressure correlated with an increased risk of
hospitalization. Some of these patients had cardiorenal limitations to PAPlowering, and we speculate that others likely had irreversible pulmonary
hypertension indicative of more advanced HF. The role of acute vasodilator
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studies in predicting hemodynamic and clinical responsiveness to ambulatory,
pressure guided HF management is not known.
A strength of our analysis compared to previous real world publications is that
patients were selected for sensor implant only after optimization of standard
medical therapy by HF specialists. Continuity of care through the same HF
specialty clinic pre- and post-implant reduces the likelihood that under treatment of
HF prior to implant, rather than PAP-guidance, was the source of benefit. Patients
with HFrEF were treated with maximal medical therapy and device therapy, as
tolerated. Additionally, following implant, patients in this study were managed
according to a nurse-implemented management algorithm with HF physician
oversight. Management by a limited team of providers using an empiric algorithm
(Appendix) reduces variability in treatment approach and strengthens the
generalizability of our findings.
Included in this analysis are 4 patients with continuous flow left ventricular assist
devices (LVAD) implanted as destination therapy. One patient experienced
progressive deterioration and required durable LVAD implantation 2 months after
sensor implant; due to concern about the patient’s candidacy for an LVAD, the
sensor was implanted with the intention of preventing or delaying the need for
surgery. We successfully managed three other LVAD patients who had persistent
NYHA class III symptoms following LVAD implant. In total, all four LVAD patients
had improved hemodynamics and reduced hospitalizations following
CardioMEMS™ implantation, consistent with another cases series.17 Further
research is needed to optimize selection and management of patients with
advanced co-morbid conditions and prior to and after LVAD implantation.
An analysis of medical claims data from 1114 patients implanted with
CardioMEMSTM in a real-world setting found a 34% reduction in HF
hospitalizations at one year, which correlated to cost reductions of $11,260 per
patient.11 We could therefore reasonably expect significant cost-savings
associated with our results of a 72% reduction in HF hospitalizations at one year
post-implant. Cost-effectiveness analysis was outside of the scope of this study;
however, our workload analysis suggests that with less than one medication
adjustment per patient per month, CardioMEMS™ monitoring is feasible and
scalable as part of a population health strategy for HF.
There were no complications associated with device implantation. Of interest, 34%
of patients were implanted as outpatients via the right internal jugular vein.
Although this access route is not mentioned in the CardioMEMS™ sensor FDA
approval, it has become the preferred approach at our center and allows for
continuation of anticoagulation, earlier patient mobilization post-procedure, and
faster time to discharge.18
This study has a number of limitations. First, the overall sample size is small and
drawn from a single-center. Sample size notwithstanding, our findings are
statistically and clinically significant, concordant with the results of larger studies,
and reflect treatment of a real-world, representative HF patient population.
Second, as a pre-/post-implant design is employed, we cannot exclude the
potential for selection bias or confounding by other HF interventions that were
The VAD Journal: https://doi.org/10.13023/vad.2019.01
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applied in the post-implant interval. However, because all patients were managed
by the same experienced HF team before and after implant, it is less likely there
were significant differences in treatment before and after sensor implant. Third, the
physicians implanting and managing patients were HF specialists experienced with
pressure-guided HF management, potentially limiting generalizability. This
limitation is minimized by the use of a treatment algorithm that was implemented
by clinic nursing. Finally, while we report the number of medication adjustments as
a reflection of clinical workload, we are not able to measure the additional time and
effort needed for reviewing pressure data, contacting patients, troubleshooting the
device, and educating patients.

Conclusions
This analysis of a single center experience with hemodynamic-guided HF
management using an implantable sensor shows that improvements in
hemodynamics and clinical outcomes are achievable with an acceptable degree of
workload for clinical staff. Further studies are needed to optimize patient selection
and to assess cost-effectiveness.
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